Overview
Arenavirus infections, primarily caused by viruses such as Lymphocytic Choriomeningitis Virus (LCMV) and Lassa virus, represent a significant public health concern, particularly in endemic regions. These viruses can lead to a spectrum of clinical presentations ranging from asymptomatic infection to severe hemorrhagic fever, encephalitis, and multi-organ failure. Arenavirus disease predominantly affects individuals in close contact with infected rodents or through person-to-person transmission in some cases. Clinicians must be vigilant due to the potential for severe outcomes and the need for prompt diagnosis and intervention to prevent complications and transmission. 25Pathophysiology
Arenavirus infection initiates with viral entry into host cells, primarily mediated by α-dystroglycan, although recent studies suggest that while glycosylation is crucial in vitro, its in vivo importance may be mitigated by alternative receptors or entry pathways. Once inside the cell, the virus hijacks cellular machinery to replicate, leading to the production of viral proteins and progeny virions. This process triggers robust immune responses, including both innate and adaptive immunity. The innate immune system responds with interferon production and activation of natural killer cells, while adaptive immunity involves T cell and B cell activation. However, persistent infection can occur, particularly in cell lines like Detroit-6, where the virus establishes a non-infectious but persistent state, complicating eradication and potentially leading to chronic immune activation and tissue damage. 26Epidemiology
Arenavirus infections, notably LCMV and Lassa virus, exhibit varying incidence and prevalence rates depending on geographic location. LCMV is endemic in Europe and the Americas, with sporadic outbreaks reported, while Lassa virus is predominantly found in West Africa, affecting millions annually with a significant mortality rate among hospitalized patients. Transmission is often linked to environmental factors and human behaviors such as rodent exposure and poor sanitation. Age and sex distribution show no significant predilection, but individuals with compromised immune systems or those living in endemic areas are at higher risk. Trends indicate increasing awareness and surveillance efforts have led to better detection rates, though regional disparities persist. 5Clinical Presentation
Clinical presentations of arenavirus infections vary widely. LCMV infections are often mild or asymptomatic, with symptoms resembling a flu-like illness including fever, malaise, muscle aches, and headache. In more severe cases, neurological symptoms such as meningitis or encephalitis can occur. Lassa virus infection, on the other hand, can manifest as a hemorrhagic fever syndrome characterized by high fever, hemorrhagic manifestations, facial swelling, and gastrointestinal symptoms like vomiting and diarrhea. Red-flag features include sudden onset of high fever, petechiae, and signs of shock, necessitating urgent diagnostic evaluation and intervention. 25Diagnosis
Diagnosing arenavirus infections requires a multifaceted approach combining clinical suspicion with laboratory confirmation. Initial steps include detailed patient history focusing on potential exposure to rodents or endemic areas. Diagnostic criteria include:Management
First-Line Treatment
Second-Line and Refractory Cases
Complications
Common complications include:Prognosis & Follow-Up
The prognosis for arenavirus infections varies widely based on the specific virus and the severity of the initial presentation. Prognostic indicators include early diagnosis, prompt initiation of ribavirin therapy, and absence of severe comorbidities. Recommended follow-up intervals include:Special Populations
Key Recommendations
References
1 Xie J, Jeon H, Xin G, Ma Q, Chung D. LRT: Integrative analysis of scRNA-seq and scTCR-seq data to investigate clonal differentiation heterogeneity. PLoS computational biology 2023. link 2 Imperiali M, Spörri R, Hewitt J, Oxenius A. Post-translational modification of {alpha}-dystroglycan is not critical for lymphocytic choriomeningitis virus receptor function in vivo. The Journal of general virology 2008. link 3 Hangartner L, Senn BM, Ledermann B, Kalinke U, Seiler P, Bucher E et al.. Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America 2003. link 4 Brändle D, Bürki K, Wallace VA, Rohrer UH, Mak TW, Malissen B et al.. Involvement of both T cell receptor V alpha and V beta variable region domains and alpha chain junctional region in viral antigen recognition. European journal of immunology 1991. link 5 Wood BA, Dutz W, Cross SS. Neonatal infection with mouse thymic virus: spleen and lymph node necrosis. The Journal of general virology 1981. link 6 Gaidamovich SY, Cherednichenko YN, Zhdanov VM. On the mechanism of the persistence of lymphocytic choriomeningitis virus in the continuous cell line Detroit-6. Intervirology 1978. link 7 Webster JM, Kirk BE. Immunofluorescent cell-counting assay for lymphocytic choriomeningitis virus. Applied microbiology 1974. link